CIPLA.NS Earnings — Cipla Limited

NSE

Updated Oct 30, 2026

Price —

Market Cap $1.1T

P/E 32.0

52W Range — – —

When is CIPLA.NS's next earnings date?

Cipla Limited (CIPLA.NS) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.

How did CIPLA.NS do in its last earnings report?

In its most recent report on Oct 27, 2026, Cipla Limited posted EPS of $10.76 versus the $11.50 estimate, a miss of 6.4%. Revenue was $73.40B against a $76.15B estimate.

How much does CIPLA.NS stock move after earnings?

CIPLA.NS beat EPS estimates in 0 of its last 2 reported quarters.

About Cipla Limited

Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.

🤖 AI Earnings Analysis

Cipla’s quarter was concerning: revenue of $73.4B missed estimates by $2.9B, while EPS of $10.76 fell $0.79 short. Despite reported 328.3% revenue growth, sharply weaker EPS points to poor earnings quality.

AI-generated summary — powered by BigEarnings.